Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors
CIAG933A12101
Phase 1 other active
Quick answer
Phase I study of IAG933 in patients with advanced Mesothelioma and other solid tumors for Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway is a Phase 1 program (other) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advanced mesothelioma or other solid tumors harboring certain molecular alterations in the Hippo pathway
- Phase
- Phase 1
- Modality
- other
- Status
- active